When did Idexx Laboratories report Q1 2025 earnings?

Idexx Laboratories (IDXX) reported Q1 2025 earnings on May 1, 2025 before market open.

What were Idexx Laboratories's Q1 2025 revenue and EPS?

Idexx Laboratories reported revenue of $998.4M and diluted EPS of $2.96 for Q1 2025.

Did Idexx Laboratories beat estimates in Q1 2025?

Revenue beat the consensus estimate of $997.1M by $1.3M. EPS beat the consensus estimate of $2.85 by $0.11.

How did Idexx Laboratories's Q1 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 3.6% from $964.1M a year earlier and diluted EPS grew 5.3% from $2.81.

Where can I find Idexx Laboratories's Q1 2025 SEC filings?

You can read the 10-Q periodic report (0000874716-25-000062) directly on SEC EDGAR. The filing index links above go to sec.gov.

Idexx Laboratories IDXX Q1 2025 earnings

Reported May 1, 2025 · Before market open

Revenue$998.4MBeat by $1.3M Diluted EPS$2.96Beat by $0.11

Revenue estimate$997.1M

EPS estimate$2.85

Next report

Aug 4, 2026 (In 3 weeks)

Revenue estimate$1.2B

EPS estimate$3.95

Financials

Q1 2025

Income statement

See full

Revenue$998.4M+3.6%

Gross profit$623.4M+5.1%

Operating income$316.5M+5.9%

Net income$242.7M+3.0%

EPS (diluted)$2.96+5.3%

Balance sheet

See full

Cash & equivalents$164.0M-58.7%

Total debt$739.9M-9.7%

Total equity$1.4B-7.7%

Total assets$3.2B-4.2%

Cash flow

See full

Operating cash flow$238.0M+19.8%

CapEx$30.0M-0.8%

Free cash flow$207.9M+23.5%

Valuation & ratios

Valuation

as of 03/31/25

See full

Market cap$34.03B-24.1%

Enterprise value$34.61B-23.6%

P/E38×-13.7×

P/S8.7×-3.4×

Profitability

See full

Gross margin61.3%+1.1pp

Operating margin29.1%-0.8pp

Net margin22.8%-0.5pp

FCF margin21.6%+0.2pp

Returns & leverage

See full

Return on equity59.3%-12.6pp

Debt / equity0.5×0.0×

Current ratio1.2×-0.4×

Segments

By geography

See full

United States$654.9M—

Germany$51.7M—

United Kingdom$38.6M—

Canada$37.3M—

France$31.5M—

By product

See full

IDEXX VetLab consumables$344.8M+8.8%

Reference laboratory diagnostic and consulting services$344.4M0.0%

Rapid assay products$84.0M-2.6%

Recurring revenue$65.8M+10.2%

CAG Diagnostics services and accessories$33.0M+1.5%

By segment

See full

CAG$919.8M—

Water segment revenue$45.3M+5.2%

LPD$28.6M+1.4%

Versus estimates

Revenue

Q1 2026$1.1BBeat by $22.3M Q4 2025$1.1BBeat by $17.9M Q3 2025$1.1BBeat by $32.0M Q2 2025$1.1BBeat by $47.1M

Q1 2025$998.4MBeat by $1.3M

Q4 2024$954.3MBeat by $19.1M

Diluted EPS

Q1 2026$3.47Beat by $0.06 Q4 2025$3.08Beat by $0.15 Q3 2025$3.40Beat by $0.26 Q2 2025$3.63Beat by $0.35

Q1 2025$2.96Beat by $0.11

Q4 2024$2.62Beat by $0.23

Ask the moment Idexx Laboratories reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Idexx Laboratories report Q1 2025 earnings?: Idexx Laboratories (IDXX) reported Q1 2025 earnings on May 1, 2025 before market open.
What were Idexx Laboratories's Q1 2025 revenue and EPS?: Idexx Laboratories reported revenue of $998.4M and diluted EPS of $2.96 for Q1 2025.
Did Idexx Laboratories beat estimates in Q1 2025?: Revenue beat the consensus estimate of $997.1M by $1.3M. EPS beat the consensus estimate of $2.85 by $0.11.
How did Idexx Laboratories's Q1 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 3.6% from $964.1M a year earlier and diluted EPS grew 5.3% from $2.81.
Where can I find Idexx Laboratories's Q1 2025 SEC filings?: You can read the 10-Q periodic report (0000874716-25-000062) directly on SEC EDGAR. The filing index links above go to sec.gov.